Aethlon Medical, Inc. (NASDAQ:AEMD) tinted gains of +1.54% (+0.02 points) to US$1.32. The volume of 0.14 Million shares climbed down over an trading activity of 261.29 Million shares. EPS ratio determined by looking at last 12 month figures is -0.65. Over the same time span, the stock marked US$3.85 as its best level and the lowest price reached was US$0.79. The corporation has a market cap of US$22.1 Million.
Aethlon Medical, Inc. (NASDAQ:AEMD)’s earnings per share has been growing at a 25.1 percent rate over the past 5 year when average revenue increase was noted as -22 percent. The return on equity ratio or ROE stands at -523.8 percent while most common profitability ratio return on investment (ROI) was -554.7 percent. The company’s institutional ownership is monitored at 16.7 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 2. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Novanta Inc. (NASDAQ:NOVT) is worth US$2.16 Billion and has recently risen 1.54% to US$62.8. The latest exchange of 0.17 Million shares is below its average trading activity of 222.27 Million shares. The day began at US$61.9 but the price moved to US$61.25 at one point during the trading and finally capitulating to a session high of US$62.35. The stock tapped a 52-week high of US$66.25 while the mean 12-month price target for the shares is US$56.
Currently, the stock carries a price to earnings ratio of 63.5, a price to book ratio of 6.88, and a price to sales ratio of 3.85. For the past 5 years, the company’s revenue has grown 16.4%, while the company’s earnings per share has grown 14.3%. With an institutional ownership near 85%, it carries an earnings per share ratio of 0.99.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.